“Our effects show that the myocarditis threat of being inflamed with COVID-19 is much greater than getting the vaccine,” said Dr. Brown. Navya Voleti, resident physician in the Department of Medicine at Penn State Health’s Milton S. Hershey Medical Center. “In the future, it will be to monitor possible long-term effects on those who develop myocarditis. “
Myocarditis is one of the headaches of SARS-CoV-2 infection. Although vaccines have been shown to reduce severe COVID-19 symptoms, heart headaches have been linked to COVID-19 mRNA vaccination, namely myocarditis in adolescents. However, the relative threat of myocarditis from vaccines and infections not well characterized in giant studies.
The Penn State team conducted the largest study to date on the risk of myocarditis as a result of having the coronavirus rather than inflammation after COVID-19 vaccination. The researchers compared COVID-19 patients, vaccinated and unvaccinated, with those without the virus. They found that the risk of myocarditis was 15 times higher in COVID-19 patients, regardless of vaccination status, compared to other people who did not contract the virus.
The researchers then compared the rates of myocarditis in those who received the vaccines with those who did not. According to the results, rates of myocarditis in other people vaccinated against COVID-19 were only twice as high as in other unvaccinated people.
Based on all the findings, the researchers concluded that the threat of myocarditis due to COVID-19 is seven times greater than the threat from vaccines.
Researchers conducted a systematic review and meta-analysis of 22 internationally published studies from December 2019 to May 2022. The studies included almost 58 million people who reported central headaches and belonged to one of two groups: 55. 5 million who were vaccinated instead of COVID-19 compared to those who were not vaccinated (vaccination group), and 2. 5 million who became infected with the virus compared to those who did not contract the virus (COVID-19 group).
In the vaccination group, researchers separately compared the risk of myocarditis for COVID-19 vaccines, adding mRNA (Pfizer, Moderna), Novavax, AstraZeneca, and Johnson and Johnson. The median age of the population examined was 49 years; 49 per cent were men; and median follow-up time after COVID-19 infection or vaccination was 28 days.
The researchers found that among those diagnosed with myocarditis after receiving the vaccine or having COVID-19, the majority (61%) were men. % died.
Please indicate the appropriate maximum category to facilitate the processing of your request
Thank you for taking the time to provide feedback to the editors.
Your opinion is for us. However, we do not guarantee individual responses due to the large volume of messages.